The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.
Our work on the ultrastructure of the periodic actin/spectrin scaffold along axons is out in Nature Communications.
In a large cohort of 911 high-grade IDH-mutant gliomas from the French national POLA network, we investigated the prognostic value of the CDKN2A gene homozygous deletion as well as WHO grading criteria (mitoses, microvascular proliferation, and necrosis).
We showed that:
- CDKN2A homozygous deletion characterizes diffuse malignant IDH-mutant gliomas with worst outcome.
- Microvascular proliferation stratifies IDH-mutant gliomas lacking CDKN2A homozygous deletion.
On thursday december the 12th, most of INP and Vect-Horus members got together and spent a day in the Black Stone pub, Marseille, to celebrate the fact that nearly two years after its creation, the Institute of NeuroPhysiopathology is finally located on Tmone Campus.
Michel KHRESTCHATISKY, Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS and co-founder of VECT-HORUS was invited at the third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS and hosted by BioFIT on December 10, 2019 (https://www.biofit-event.com/translational-neuroscience).
Maeva and Noé presented their poster at the SFNano C'Nano conference entitled "Preclinical evaluation of a paclitaxel nanoprodrug for glioblastoma therapy".
L'équipe 5 a le plaisir d'accueillir en stage du 1er décembre 2019 au 31 mars 2020, Théo Loignon étudiant à l'école d'ingénieur de Bordeaux ei.cesi. Théo travaillera avec Jean-Philippe Dales sur l'imagerie chimique du tissu nerveux au cours de la neuroinflammation.
In this paper, Daniel Bertin evaluated the immunological follow-up of patients suffering from chronic inflammatory diseases and receiving anti-TNF biotherapy. Three commercial ELISA assays for monitoring soluble through levels of infliximab and anti-infliximab antibodies in serum showed a good global correlation of results. However, some quantitative discrepancies could change clinical decision. As a consequence, Daniel Bertin recommended to keep the same kit to perform a longitudinal follow-up of patients.
Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, in the Insitute of NeuroPhysiopathology, UMR CNRS 7051, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response".
Subsequently she was interviewed by :
- France 3 (JT 19/20 PACA diffusion du 15/11: 7'09 à 9'45) ;
- Provence Azur (18/11/2019) ;
- 20 Minutes Marseille (18/11/2019)
- La Provence
L'équipe 5 a le plaisir d'accueillir en stage du 1er décembre 2019 au 31 mars 2020, Théo Loignon étudiant à l'école d'ingénieur de Bordeaux ei.cesi. Théo travaillera avec Jean-Philippe Dales sur l'imagerie chimique du tissu nerveux au cours de la neuroinflammation.
In this paper, Daniel Bertin evaluated the immunological follow-up of patients suffering from chronic inflammatory diseases and receiving anti-TNF biotherapy. Three commercial ELISA assays for monitoring soluble through levels of infliximab and anti-infliximab antibodies in serum showed a good global correlation of results. However, some quantitative discrepancies could change clinical decision. As a consequence, Daniel Bertin recommended to keep the same kit to perform a longitudinal follow-up of patients.
Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, in the Insitute of NeuroPhysiopathology, UMR CNRS 7051, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response".
Subsequently she was interviewed by :
- France 3 (JT 19/20 PACA diffusion du 15/11: 7'09 à 9'45) ;
- Provence Azur (18/11/2019) ;
- 20 Minutes Marseille (18/11/2019)
- La Provence
Vous êtes médecin, pharmacien, interne en médecine ou biologie médicale et intéressé par les maladies auto-immunes et inflammatoires chroniques ?
Our data show that VEGF blockade leads to an increased recruitment of monocytes and to an adjustment of dendritic cell subsets’ profiles, differing in their ability to induce an adaptive immune response. Altogether, they provide important new insights into the effects of Bevacizumab at the cellular level and into the spatio-temporal evolution of intra-tumoral innate immune cell densities.
The leading peer-reviewed journal dedicated to understanding of the vital impact of oxygen and oxidation-reduction (redox) processes on human health and disease, exploring key issues in genetic, pharmaceutical, and nutritional redox-based therapeutics.
For more information, head to the ARS website.
Congratulations to all the CNRS team for running the Marseille-Cassis race two weekends ago, and especially to Claude Villard (7th from the left, top row), INP team 9 and PINT facility member who ran this semi-marathon in 1 hour and 48 minutes.
Next year, let's make a whole INP team (as usual, the race will take place on the last Sunday of October)!
For more information, head to the race's official website.
During the NeuroStories event, held on Monday October 7 at the Faculty of Medicine, Anne-Marie François Bellan gave a remarkable stand up on how our body vibrates to the rhythm of internal chronometers called circadian clocks. She also explained how the molecular clock uses small corpuscles and cell space to make our genes rhythm.
Click on the news to see the video of her brilliant speech.
The cIMPACT-NOW Working Committee is the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. cIMPACT-NOW was created in late 2016 —following publication of the 2016 Updated 4th Edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System— to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications.
During the 14th EANO annual meeting 3 members of INP team #8 presented their work on Glioma in a plenary conference «CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas» Dominique Figarella Branger, a short talk «Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls» Emeline Tabouret and two posters «P11.06: Non epigenetic effect of vorinostat
Aix Marseille Université | All rights reserved - Legal notice
